| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_60da379fb33c192ef77f86a60c5ac029
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_909010797e770591709aec08e2776d19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_587dbef48db0d6e9c729d1c3d4908b67
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9663370626ed80afe822ecc6b5e7be0e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_555f9876aaa298e49dd2a9b4d719a18a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10T436-25375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-916 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-485 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N1-18 |
| filingDate |
2010-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2013-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_07d832bde8053d0e95efbea8de516110
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d4432db225e059b5b116ecbfb3d822ac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f69be0dc515a4e75e0f0490fc8c8f297
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db91957a23297a0236d3d142f9475650 |
| publicationDate |
2013-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8546095-B2 |
| titleOfInvention |
Methods for determination of calcineurin activity and uses in predicting therapeutic outcomes |
| abstract |
The methods of the disclosure provide fluorescence-based assays for calcineurin activity, especially in isolated T cells. The methods include the stimulation of the T cells with agents that specifically target the TCR with or without influencing co-stimulatory pathways. One TCR agonist is monoclonal antibodies specific for CD3, which more precisely distinguish the inducible activity of calcineurin than does an alternative method targeting the T cell receptor (CD3) combined with CD28 costimulation. This method more accurately distinguishes between the measured level of calcineurin activity of T cells from immunosuppressed transplant recipients and normal individuals, and thus has improved diagnostic accuracy with respect to the response of an individual to immunosuppressant therapy following an organ transplant. |
| priorityDate |
2007-08-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |